Literature DB >> 22006860

Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation.

Benjamin H Friedman1, Joshua H Wolf, Liqing Wang, Mary E Putt, Abraham Shaked, Jason D Christie, Wayne W Hancock, Kim M Olthoff.   

Abstract

Early allograft dysfunction (EAD) occurring in the first week post-liver transplantation is associated with increased graft failure and mortality and is believed to be largely due to ischemia/reperfusion injury. We anticipated that the presence of EAD would be reflected by alterations in expression of serum proteins associated with an inflammatory response in the peri-operative period, and hypothesized that a specific pattern of expression might correlate with the development of EAD. The serum levels of 25 cytokines, chemokines, and immunoreceptors were measured by Luminex multiplex assays pre- and post-liver transplantation. Levels of each cytokine biomarker were compared in adult recipients with or without EAD at serial time points using samples collected pre-operatively and at 1, 7, 14, and 30 days post-transplant. EAD was defined according to standard criteria as maximum alanine transferase (ALT) or aspartate transferase (AST) levels on days 1-7 of >2000 U/ml, day 7 bilirubin level ≥10 mg/dl, or a day 7 international normalized ratio (INR) ≥1.7. Multivariable analyses showed that patients experiencing EAD had lower pre-operative IL-6 and higher IL-2R levels. Patients with EAD also showed higher MCP-1 (CCL2), IL-8 (CXCL8), and RANTES (CCL5) chemokine levels in the early post-operative period, suggesting up-regulation of the NF-kB pathway, in addition to higher levels of chemokines and cytokines associated with T cell immunity, including MIG (CXCL9), IP-10 (CXCL10) and IL-2R. These findings identify several possible biomarkers and pathways associated with EAD, that may guide future validation studies and investigation of specific cellular and molecular mechanisms of graft dysfunction. Furthermore, if validated, our findings may contribute to perioperative prediction of the occurrence of EAD and ultimately lead to identification of potential interventional therapies.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22006860      PMCID: PMC3266982          DOI: 10.1002/lt.22451

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  29 in total

1.  Factors predicting perioperative cytokine response in patients undergoing liver transplantation.

Authors:  C Miki; P McMaster; A D Mayer; K Iriyama; H Suzuki; J A Buckels
Journal:  Crit Care Med       Date:  2000-02       Impact factor: 7.598

Review 2.  Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression.

Authors:  Wayne W Hancock; Liqing Wang; Qunrui Ye; Rongxiang Han; Iris Lee
Journal:  Curr Opin Immunol       Date:  2003-10       Impact factor: 7.486

3.  Early post-operative measurement of cytokine plasma levels combined with pre-operative bilirubin levels identify high-risk patients after liver resection.

Authors:  Christoph W Strey; Rosa Maria Marquez-Pinilla; Maciej M Markiewski; Britta Siegmund; Elsie Oppermann; John D Lambris; Wolf O Bechstein
Journal:  Int J Mol Med       Date:  2010-12-28       Impact factor: 4.101

4.  Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation.

Authors:  H Tilg; W Vogel; W E Aulitzky; M Herold; A Königsrainer; R Margreiter; C Huber
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

5.  Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine.

Authors:  S Suzuki; L H Toledo-Pereyra; F J Rodriguez; D Cejalvo
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

6.  In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats.

Authors:  Zhaoli Sun; Andrew S Klein; Svetlana Radaeva; Feng Hong; Osama El-Assal; Hong-Na Pan; Barbara Jaruga; Sandor Batkai; Sumito Hoshino; Zhigang Tian; George Kunos; Anna Mae Diehl; Bin Gao
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

7.  Cytokine-induced neutrophil chemoattractant release from hepatocytes is modulated by Kupffer cells.

Authors:  E Mawet; Y Shiratori; Y Hikiba; H Takada; H Yoshida; K Okano; Y Komatsu; M Matsumura; Y Niwa; M Omata
Journal:  Hepatology       Date:  1996-02       Impact factor: 17.425

Review 8.  The utility of marginal donors in liver transplantation.

Authors:  Ronald W Busuttil; Koichi Tanaka
Journal:  Liver Transpl       Date:  2003-07       Impact factor: 5.799

Review 9.  Biologic basis for interleukin-1 in disease.

Authors:  C A Dinarello
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

Review 10.  Chemokine receptor-dependent alloresponses.

Authors:  Wayne W Hancock
Journal:  Immunol Rev       Date:  2003-12       Impact factor: 12.988

View more
  28 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 2.  Immune Cell Trafficking to the Liver.

Authors:  Sulemon Chaudhry; Jean Emond; Adam Griesemer
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

3.  The combination of indocyanine green clearance test and model for end-stage liver disease score predicts early graft outcome after liver transplantation.

Authors:  Tang Yunhua; Ju Weiqiang; Chen Maogen; Yang Sai; Zhang Zhiheng; Wang Dongping; Guo Zhiyong; He Xiaoshun
Journal:  J Clin Monit Comput       Date:  2017-08-22       Impact factor: 2.502

4.  Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis.

Authors:  Patrizia Farci; Kurt Wollenberg; Giacomo Diaz; Ronald E Engle; Maria Eliana Lai; Paul Klenerman; Robert H Purcell; Oliver G Pybus; Harvey J Alter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-24       Impact factor: 11.205

Review 5.  Genomics of liver transplant injury and regeneration.

Authors:  Sohaib Khalid Hashmi; Esther Baranov; Ana Gonzalez; Kim Olthoff; Abraham Shaked
Journal:  Transplant Rev (Orlando)       Date:  2014-03-04       Impact factor: 3.943

Review 6.  Biomarkers in Transplantation--Proteomics and Metabolomics.

Authors:  Uwe Christians; Jelena Klawitter; Jost Klawitter
Journal:  Ther Drug Monit       Date:  2016-04       Impact factor: 3.681

7.  Expressional time phase of leukocyte molecules induced by allogenic cardiac antigen and cyclosporin A in rats' in vitro model.

Authors:  Xiu-Fang Xu; Yi Xin; Ying Zhang; Yi-Min Huang; Yun Gu; Na Li; Wen-Bin Li; Yu-Jie Zhou; Zhao-Guang Zhang
Journal:  Int J Clin Exp Med       Date:  2013-05-22

8.  Impact of Rifaximin Therapy on Ischemia/Reperfusion Injury in Liver Transplantation: A Propensity Score-Matched Analysis.

Authors:  Takahiro Ito; Kojiro Nakamura; Shoichi Kageyama; Islam M Korayem; Hirofumi Hirao; Kentaro Kadono; Justine Aziz; Stephanie Younan; Joseph DiNorcia; Vatche G Agopian; Hasan Yersiz; Douglas G Farmer; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Fady M Kaldas
Journal:  Liver Transpl       Date:  2019-11-04       Impact factor: 5.799

9.  The Macrophage Activation Marker Soluble CD163 is Associated With Early Allograft Dysfunction After Liver Transplantation.

Authors:  Karen L Thomsen; Francis P Robertson; Peter Holland-Fischer; Brian R Davidson; Rajeshwar P Mookerjee; Holger J Møller; Rajiv Jalan; Henning Grønbæk
Journal:  J Clin Exp Hepatol       Date:  2018-10-05

Review 10.  Osteopontin and Transplantation: Where Are We Now?

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-21       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.